SLDB
What one share of Solid Biosciences holds
Biological Products, (No Diagnostic Substances)
We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (“Duchenne”), SGT-212 for the treatment of Friedreich’s ataxia (“FA”), SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia (“CPVT”), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy (“TNNT2 DCM”), and…
Solid Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.87 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.70 |
| Cash and investments | $1.52 |
| Book value | $3.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$152.13 | $3.46 | −$181.10 | — | −$334.50 |
| 2017 | $0.00 | −$43.21 | $2.50 | −$50.00 | — | — |
| 2018 | $0.00 | −$33.73 | $3.51 | −$35.16 | — | $53.00 |
| 2019 | $0.00 | −$43.64 | $1.63 | −$36.15 | — | $26.11 |
| 2020 | $0.00 | −$25.50 | $0.26 | −$16.61 | — | $23.34 |
| 2021 | $1.91 | −$10.14 | $0.18 | −$11.10 | — | $28.30 |
| 2022 | $0.95 | −$10.10 | $0.35 | −$11.86 | — | — |
| 2023 | — | −$4.83 | $0.08 | −$4.81 | — | $6.20 |
| 2024 | — | −$3.06 | $0.02 | −$2.47 | — | $3.39 |
| 2025 | — | −$1.99 | $0.01 | −$1.80 | — | $2.28 |